Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program
By Colin Kellaher
Gilead Sciences has signed an exclusive license agreement to develop and commercialize Xilio Therapeutics' tumor-activated IL-12 program in a deal potentially worth hundreds of millions of dollars to the clinical-stage biotechnology company.
Gilead and Xilio on Thursday said the deal includes Xilio's XTX301, which is currently being evaluated in a Phase 1 dose-escalation study in patients with advanced solid tumors.
The Foster City, Calif., biopharmaceutical company said it will make $43.5 million in upfront payments to Xilio, including a $30 million cash payment and an initial equity investment of $13.5 million.
The companies said Xilio is also eligible to receive up to $604 million in additional contingent payments, including additional equity investments, along with royalties on product sales.
Xilio, based in Waltham, Mass., has a current market capitalization of around $18.2 million based on Wednesday's closing price of about 64 cents. Trading in Xilio shares was halted premarket on Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 28, 2024 07:33 ET (11:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth